Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination

6th January 2026 Uncategorised 0

Company aims to expand treatment options for relapsed or refractory multiple myeloma

More: Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
Source: News